GHRS News and Press, GH Research PLC From 03/28/22

GH Research press release (NASDAQ:GHRS): FY GAAP EPS of -$0.21 beats by $0.13. Cash was $276.8 million as of December 31, 2021, compared to $5.9 million as of December 31, 2020. For further details see: GH Research GAAP EPS of -$0.21 beats by $0.13

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and g...

The following slide deck was published by GH Research PLC in conjunction with this event. For further details see: GH Research (GHRS) Investor Presentation - Slideshow

NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response...

The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market. The COVID-19 pandemic has also created massive opportunities for biotechnology companies. According...

GH Research (NASDAQ:GHRS): Q3 GAAP EPS of -$0.04 beats by $0.06. Cash was $280.7 million as of September 30, 2021, compared to $5.9 million as of December 31, 2020. Press Release For further details see: GH Research EPS beats by $0.06

Psychedelic biotech company GH Research PLC (Nasdaq: GHRS) reported financial results for the third quarter ended September 30, 2021, and gave updates on its business. R&D expenses were $2.6 million for the quarter ended September 30, 2021, compared to $55 thousand for the...

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 an...

Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change from baseline in MADRS at day 7 after dosing was -24.4 points ...

Gainers: ABVC BioPharma (NASDAQ:ABVC) +250%, ANI Pharmaceuticals (NASDAQ:ANIP) +51%, Artelo Biosciences (NASDAQ:ARTL) +37%, Nutriband (NTRBW) +34%, Regencell Bioscience (NASDAQ:RGC) +15%. Losers: Centessa Pharmaceuticals (NASDAQ:CNTA) -19%, Mi...